截至发稿，仙乐健康市值为77亿元。 每经头条（nbdtoutiao）——雷军挥泪"斩"王腾，小米爱将泄密"失街亭"，大厂正风肃纪"拼牙口" （记者 王晓波） 每经AI快讯，仙乐健康（SZ 300791，收盘价：25元）9月9日晚间发布公告称，仙乐健康科技股份有限 公司于2025年9月9日收到公司副总经理、代理财务负责人郑丽群女士出具的《关于增持公司股份的告知 函》，基于对公司未来持续稳定发展的信心以及对公司股票长期投资价值的认可，郑丽群女士于2025年 9月8日以其自有资金通过深圳证券交易所交易系统以大宗交易方式增持公司股份14万股，占公司总股本 剔除公司回购证券专用账户中的股份后股本总数约3.06亿股的0.05%。 2025年1至6月份，仙乐健康的营业收入构成为：软胶囊占比46.38%，软糖占比25.31%，片剂占比 9.26%，功能饮品占比5.42%，硬胶囊占比5.31%。 ...

| 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2025-087 | | --- | --- | --- | | 证券代码：123113 | 证券简称：仙乐转债 | | 仙乐健康科技股份有限公司 关于高级管理人员增持公司股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 仙乐健康科技股份有限公司（以下简称"公司"）于 2025 年 9 月 9 日收到公 司副总经理、代理财务负责人郑丽群女士出具的《关于增持公司股份的告知函》， 基于对公司未来持续稳定发展的信心以及对公司股票长期投资价值的认可，郑丽 群女士于 2025 年 9 月 8 日以其自有资金通过深圳证券交易所交易系统以大宗交 易方式增持公司股份 140,000 股，占公司总股本剔除公司回购证券专用账户中的 股份后股本总数 306,033,360 股的 0.05%。现将相关情况公告如下： 一、增持主体基本情况 1、增持主体：公司副总经理、代理财务负责人郑丽群女士。 2、本次增持前持股情况：郑丽群女士在本次增持前持有公司股份 354,632 股，占公司总股本剔除公司回购证券专用账户中 ...

2025 年 9 月 5 日投资者关系活动记录表 仙乐健康科技股份有限公司 投资者关系活动记录表 证券代码：300791 证券简称：仙乐健康 证券代码：123113 证券简称：仙乐转债 仙乐健康科技股份有限公司 编号： 2025-004 投资者关系 活动类别 □特定对象调研 □分析师会议 □媒体采访 ■业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（ ） 参与单位名称 及人员姓名 投资者网上提问 时间 2025 年 9 月 5 日 15:30-17:30 方式 公司通过"全景·路演天下"（https://rs.p5w.net/）采用网络远程的方式 召开业绩说明会 上市公司 接待人员姓名 公司董事长兼总经理：林培青 副总经理、代理财务负责人：郑丽群 副总经理、董事会秘书：刘若阳 独立董事：高见 保荐代表人：刘兴德 投资者关系活 动主要内容介 问题：美洲市场收入同比增长 4.26，其中出口业务克服关税影响同增 7.4，请问公司是如何应对关税问题，未来在美洲市场有什么具体的拓展 1 仙乐健康科技股份有限公司 投资者关系活动记录表 绍 计划 答：公司积极采取多种手段控制对等关税对美出口业务的影响：首先，公 ...

Investment Rating - The report rates the health supplement industry as "Outperform" [1] Core Insights - The health supplement industry is entering a new upward cycle, driven by rising health awareness among younger consumers and the emergence of new consumption trends [6][9] - The market for nutritional health products in China is projected to reach 522.3 billion yuan by 2024, with a compound annual growth rate of 5.7% from 2019 to 2024 [10][11] - Online sales channels are becoming increasingly important, with a significant rise in sales through platforms like Douyin, which has become the leading online sales platform for health supplements [32][35] Summary by Sections Industry Characteristics - The industry is characterized by a clear trend towards younger consumers, the emergence of new niche markets, and accelerated product iteration [7][9] - The overall scale of the traditional health supplement market is over 300 billion yuan, growing at approximately 5% annually, while new consumption segments such as anti-aging and cardiovascular health are emerging [9] Market Dynamics - The online sales of health supplements in China grew from 107.4 billion yuan in 2022 to 142.1 billion yuan in 2023, indicating a strong shift towards e-commerce [29][30] - Douyin's sales growth in health supplements reached 38% in the first half of 2025, surpassing other platforms like Tmall and JD [32] Key Segments - The report identifies several high-growth segments within the health supplement industry: - Anti-aging: Focused on products like ergothioneine and NAD+ [49][52] - Sports nutrition: Emphasizing glucosamine and calcium products [55] - Cardiovascular health: Highlighting deep-sea fish oil and phospholipid products [58] - Liver health: Addressing needs arising from unhealthy lifestyles [61] - Probiotics: Targeting gut health and overall wellness [66] Investment Recommendations - The report suggests focusing on brands with strong product operation capabilities and high brand recognition, such as Ruoyuchen and H&H International Holdings [5][69] - For production, it recommends selecting leading companies with substantial scale and customer resources, such as Xianle Health [5][69] - In the raw material sector, it highlights industry leaders like Jindawei [5][69]

Core Viewpoint - The food and beverage industry is experiencing a mixed performance, with some companies showing growth while others face challenges due to market adjustments and inventory pressures [2][8][9]. Market Performance - The Shanghai and Shenzhen 300 Index fell by 0.81%, while the Shenwan Food and Beverage Index decreased by 1.5% during the specified period [1]. - The top five gaining stocks included Huanlejia, Gaisi Food, Qianwei Yangchu, Baihe Co., and Huifa Food [1]. Institutional Insights - Open-source Securities suggests focusing on three lines: national mid-to-high-end recovery, regional leaders, and high-end liquor valuation recovery [2]. - Key companies to watch include Shede Liquor, Shanxi Fenjiu, Gujing Gongjiu, and Moutai, with a focus on new consumption trends and channels [2]. - Huachuang Securities recommends exploring new opportunities in the health product sector, particularly H&H International and Xianle Health [3]. Industry Trends - The liquor industry is undergoing a rational adjustment, with companies like Moutai and Zhenjiu Liudu exploring new paths to enhance market reach [7]. - The white liquor sector is seeing a significant inventory issue, with 20 listed liquor companies holding nearly 170 billion yuan in inventory, leading to cash flow pressures for some mid-tier companies [9]. Company Developments - Wuliangye has launched a promotional campaign allowing car buyers to purchase its liquor at a 25% discount [10][11]. - Yingjia Gongjiu has established a new sales company to enhance its market presence [12]. - Jiusuan Co. has adjusted its growth strategy, focusing on maintaining market share rather than absolute growth [13]. Macro Events - The Chinese warehousing index for August was reported at 49.3%, indicating a decline in new orders and a slowdown in goods turnover, which may impact the food and beverage sector [4]. - The emergence of H5N1 avian influenza in the UK could have implications for poultry-related food products [5]. Financial Metrics - The financial performance of the liquor industry shows a significant disparity, with 15 out of 21 listed companies reporting revenue declines, while only six managed to achieve growth [8]. - The industry is expected to face continued challenges, with some analysts predicting a prolonged adjustment period before recovery [8]. Inventory and Capacity Issues - Many liquor companies are struggling with high inventory levels, with some facing a six-year inventory turnover cycle, which could further strain cash flow [9]. - Despite low capacity utilization rates, some companies continue to expand production, raising concerns about future inventory management [9].

（文章来源：证券日报） 证券日报网讯 9月4日晚间，仙乐健康发布公告称，公司于2025年8月4日召开2025年第三次临时股东大 会，审议通过了《关于变更公司注册资本及修订〈公司章程〉的议案》。公司于近日完成了工商变更登 记手续，并取得了汕头市市场监督管理局换发的营业执照。 ...

| 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2025-086 | | --- | --- | --- | | 证券代码：123113 | 证券简称：仙乐转债 | | 仙乐健康科技股份有限公司 关于完成工商变更登记并取得换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 仙乐健康科技股份有限公司（以下简称"公司"）于 2025 年 8 月 4 日召开 2025 年第三次临时股东大会，审议通过了《关于变更公司注册资本及修订〈公 司章程〉的议案》。公司于近日完成了工商变更登记手续，并取得了汕头市市场 监督管理局换发的营业执照。现将相关情况公告如下： 一、本次工商变更登记的主要事项 公司注册资本由贰亿叁仟伍佰捌拾柒万贰仟捌佰捌拾元变更为叁亿零柒佰 叁拾壹万捌仟玖佰陆拾元。 二、新取得营业执照的基本信息 统一社会信用代码：91440500617536366K 名称：仙乐健康科技股份有限公司 类型：其他股份有限公司(上市) 法定代表人：林培青 注册资本：叁亿零柒佰叁拾壹万捌仟玖佰陆拾元 成立日期：1993 年 08 月 16 日 住所 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [6] Core Views - The company reported a total revenue of 2.042 billion yuan for H1 2025, representing a year-on-year increase of 2.57%. The net profit attributable to shareholders was 161 million yuan, up 4.3% year-on-year, while the net profit excluding non-recurring items was 159 million yuan, an increase of 3.25% year-on-year [2][4] - In Q2 2025, the company achieved a total revenue of 1.087 billion yuan, reflecting a year-on-year growth of 4.66%. The net profit attributable to shareholders was approximately 92.5 million yuan, a 1.13% increase year-on-year, and the net profit excluding non-recurring items was about 94.4 million yuan, up 5.46% year-on-year [2][4] - The company experienced varied performance across regions, with revenue in China declining by 1.63% to 818 million yuan, while revenue in the Americas grew by 4.26% to 760 million yuan, and Europe saw a significant increase of 21.96% to 359 million yuan [10] - The company's gross profit margin improved by 1.14 percentage points to 33.18% in H1 2025, while the net profit margin increased by 0.13 percentage points to 7.89% [10] - The company is expected to benefit from the aging population and changes in consumer habits post-public health events, leading to a stable upward trend in the health supplement industry [10] - Forecasted net profits for the company are 353 million yuan, 455 million yuan, and 535 million yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 1.15, 1.48, and 1.74 yuan, and PE ratios of 21, 16, and 14 times [10]

Group 1 - Xianle Health's stock price has declined by 2.7% on September 3, reaching 24.10 CNY per share, with a trading volume of 81.97 million CNY and a turnover rate of 1.31%, resulting in a total market capitalization of 7.406 billion CNY [1] - The stock has experienced a continuous decline over three days, with a cumulative drop of 8.02% during this period [1] - Xianle Health, established on August 16, 1993, and listed on September 25, 2019, specializes in the research, production, sales, and technical services of nutritional health products [1] Group 2 - The main revenue composition of Xianle Health includes soft capsules (46.38%), gummies (25.31%), tablets (9.26%), beverages (5.42%), hard capsules (5.31%), powders (4.45%), and other forms (3.22%), with additional supplements accounting for 0.65% [1] - Among the top ten circulating shareholders, a fund under China Merchants Fund, specifically the China Merchants Industry Select Stock A (010341), entered the top ten in the second quarter, holding 2.2 million shares, which is 0.86% of the circulating shares [2] - The estimated floating loss for the fund today is approximately 1.474 million CNY, with a total floating loss of 4.6199 million CNY during the three-day decline [2]

Market Overview - On September 2, the food processing sector declined by 0.3% compared to the previous trading day, with Xianle Health leading the decline [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] Stock Performance - The following stocks in the food processing sector showed notable performance: - ST Chuntian (600381) closed at 5.48, up 4.98% with a trading volume of 242,300 shares and a turnover of 132 million yuan [1] - Gai Shi Food (836826) closed at 14.23, up 4.10% with a trading volume of 157,300 shares and a turnover of 223 million yuan [1] - Huadong Co. (002840) closed at 11.39, up 3.17% with a trading volume of 348,600 shares and a turnover of 395 million yuan [1] - Xianle Health (300791) closed at 24.77, down 2.94% with a trading volume of 49,100 shares and a turnover of 123 million yuan [2] Capital Flow - The food processing sector experienced a net outflow of 77.54 million yuan from institutional funds, while retail investors saw a net inflow of 127 million yuan [2]